Q4 2023 · 13F-HR
Sarissa Capital Management LPholdings as filed
Filed 2024-02-14 · accession 0000899140-24-000250
$648.9M
Reported value
9
Positions
2023-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 46333X108 | IRWD | IRONWOOD PHARMACEUTICALS INC | $187.5M | 28.9% | 16,390,000 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $166.4M | 25.6% | 643,000 | Common | SOLE |
| 45781M101 | INVA | INNOVIVA INC | $116.7M | 18.0% | 7,277,000 | Common | SOLE |
| 375558103 | GILD | GILEAD SCIENCES INC | $87.1M | 13.4% | 1,075,400 | Common | SOLE |
| 64125C109 | NBIX | NEUROCRINE BIOSCIENCES INC | $61.9M | 9.54% | 470,000 | Common | SOLE |
| 023111206 | — | AMARIN CORP PLC | $21.6M | 3.33% | 24,850,623 | Common | SOLE |
| 09058V103 | BCRX | BIOCRYST PHARMACEUTICALS INC | $6.0M | 0.92% | 1,000,000 | Common | SOLE |
| 929033108 | — | VOR BIOPHARMA INC | $1.4M | 0.21% | 618,000 | Common | SOLE |
| 75915K309 | RGLS | REGULUS THERAPEUTICS INC | $237,034 | 0.04% | 185,183 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.